Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases. Despite durable responses, almost all patients receiving PARPis...

Descripción completa

Detalles Bibliográficos
Autores principales: Uddin, Mohammed Hafiz, Zhou, Jun-Ying, Pimentel, Julio, Patrick, Steve M., Kim, Seongho, Shekhar, Malathy P., Wu, Gen Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277186/
https://www.ncbi.nlm.nih.gov/pubmed/35847859
http://dx.doi.org/10.3389/fonc.2022.908603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277186/
https://www.ncbi.nlm.nih.gov/pubmed/35847859
http://dx.doi.org/10.3389/fonc.2022.908603

Ejemplares similares